Atovaquone (Synonyms: 阿托伐醌; Atavaquone)

目錄號(hào): HY-13832 純度: 99.75%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南

摩爾計(jì)算器

Atovaquone (Atavaquone) 是一種有效的、具有口服活性的選擇性寄生蟲(chóng)線粒體細(xì)胞色素 bc1 (parasite’s mitochondrial cytochrome?bc1) 復(fù)合物的抑制劑。Atovaquone 抑制人類(lèi)和 P. falciparum?細(xì)胞色素 bc1?活性，IC₅₀ 值分別為 460 nM 和 2.0 nM。Atovaquone 是一種抗瘧 (antimalarial agent) 試劑，有潛力用于肺孢子蟲(chóng)肺炎、弓形體病、瘧疾和巴貝斯蟲(chóng)病的相關(guān)研究。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Atovaquone Chemical Structure

CAS No. : 95233-18-4

1. 客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價(jià)格	是否有貨
10 mM * 1 mL in DMSO	￥550	In-stock
1 mg	￥156	In-stock
5 mg	￥312	In-stock
10 mg	￥500	In-stock
50 mg	￥1500	In-stock
100 mg		詢價(jià)
200 mg		詢價(jià)

or 大包裝詢價(jià)

* Please select Quantity before adding items.

Customer Review

Other Forms of Atovaquone:

Atovaquone-d₄ 詢價(jià)
Atovaquone (4-chlorophenyl-2,3,5,6-d4) 詢價(jià)
Atovaquone-d₅ 詢價(jià)
cis-Atovaquone-d₄ 詢價(jià)
Atovaquone (Standard) 詢價(jià)

MCE 顧客使用本產(chǎn)品發(fā)表的 4 篇科研文獻(xiàn)

•Proc Natl Acad Sci U S A. 2024 Jun 25;121(26):e2405905121. [Abstract]
•Biomed J. 2020 Aug;43(4):368-374. [Abstract]
•ACS Omega. 2024 Feb 28;9(10):11870-11882. [Abstract]
•ChemMedChem. 2024 Jun 18:e202400292. [Abstract]

Atovaquone 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 Parasite 亞型特異性產(chǎn)品:

查看所有亞型

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

查看 Cytochrome P450 亞型特異性產(chǎn)品:

查看所有亞型

CYP1 CYP2 CYP3 CYP4 CYP11 CYP17 Aromatase/CYP19A1 CYP26 CYP51 CYP1A2 CYP2D6 CYP2C9 CYP2C19 CYP3A4 CYP17A1

查看 Antibiotic 亞型特異性產(chǎn)品:

查看所有亞型

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

生物活性
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome?bc1?complex. Atovaquone is against human and ?P. falciparum?cytochrome?bc1?activity with IC₅₀ values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia^[1]^[2].

IC₅₀ & Target

Plasmodium

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
BJ	EC₅₀	> 21.5 μM Compound: 4	Cytotoxicity against human BJ cells after 72 hrs by luminescence analysis Cytotoxicity against human BJ cells after 72 hrs by luminescence analysis	[PMID: 22435599]
DU-145	IC₅₀	29.3 μM Compound: Atovaquone	Growth inhibition of human DU145 cells after 72 hrs by MTT assay Growth inhibition of human DU145 cells after 72 hrs by MTT assay	[PMID: 19632833]
HEK293	IC₅₀	> 10000 nM Compound: 46	Inhibition of Plasmodium falciparum NDH2 expressed in HEK293 cells by spectrophotometric analysis Inhibition of Plasmodium falciparum NDH2 expressed in HEK293 cells by spectrophotometric analysis	[PMID: 26791529]
HEK293	IC₅₀	0.41 μM Compound: Atovaquone	Inhibition of human cytochrome bc1 complex derived from HEK293 cell mitochondria using 50 uM decylubiquinol as substrate Inhibition of human cytochrome bc1 complex derived from HEK293 cell mitochondria using 50 uM decylubiquinol as substrate	[PMID: 24720377]
HEK293	IC₅₀	2 nM Compound: 46	Inhibition of Plasmodium falciparum cytochrome bc1 expressed in HEK293 cells by spectrophotometric analysis Inhibition of Plasmodium falciparum cytochrome bc1 expressed in HEK293 cells by spectrophotometric analysis	[PMID: 26791529]
HEK293	CC₅₀	49 nM Compound: 18	Cytotoxicity against HEK293 cells incubated for 48 hrs by MTT assay Cytotoxicity against HEK293 cells incubated for 48 hrs by MTT assay	[PMID: 33333397]
Hepatocyte	IC₅₀	57 nM Compound: Atovaquone	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	[PMID: 18212104]
HepG2	IC₅₀	< 1 μM Compound: Atovaquone	Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin	[PMID: 23927658]
HepG2	IC₅₀	> 10 μM Compound: Atovaquone	Cytotoxicity against human HepG2 cells after 24 hrs incubation by Alamar Blue assay Cytotoxicity against human HepG2 cells after 24 hrs incubation by Alamar Blue assay	[PMID: 24720377]
HepG2	CC₅₀	> 15.6 μM Compound: Atovaquone	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34364164]
HepG2	CC₅₀	> 15.6 μM Compound: Atovaquone	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27654395]
HepG2	CC₅₀	> 15.6 μM Compound: Atovaquone	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 25791675]
HepG2	EC₅₀	> 21.5 μM Compound: 4	Cytotoxicity against human HepG2 cells after 72 hrs by luminescence analysis Cytotoxicity against human HepG2 cells after 72 hrs by luminescence analysis	[PMID: 22435599]
HepG2	CC₅₀	> 30 μM Compound: ATQ	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay	[PMID: 33620219]
HepG2	CC₅₀	> 40 μM Compound: 2	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29324340]
HepG2	IC₅₀	0.00016 μM Compound: Atovaquone	Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells after 48 hrs Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells after 48 hrs	[PMID: 24904967]
HepG2	EC₅₀	0.5 nM Compound: 37, Atovaquone	Antimicrobial activity against Plasmodium berghei sporozoites infected in 12 hrs compound pretreated human HepG2 cells assessed as reduction in viability of exoerythrocytic forms measured after 48 hrs of incubation by luciferase bioluminescence assay Antimicrobial activity against Plasmodium berghei sporozoites infected in 12 hrs compound pretreated human HepG2 cells assessed as reduction in viability of exoerythrocytic forms measured after 48 hrs of incubation by luciferase bioluminescence assay	[PMID: 24641010]
HepG2	IC₅₀	23160 nM Compound: ATV	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32390431]
HepG2	IC₅₀	23160 nM Compound: ATV	Cytotoxicity against human HepG2 cells measured after 24 to 36 hrs by resazurin dye based fluorescence assay Cytotoxicity against human HepG2 cells measured after 24 to 36 hrs by resazurin dye based fluorescence assay	[PMID: 30852885]
HepG2	IC₅₀	8496 nM Compound: ATV	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 34111350]
HepG2	IC₅₀	9 nM Compound: Atovaquone	Antiplasmodial activity against liver stage of Plasmodium yoelii 17X NL sporozoites infected in human HepG2 cells expressing CD81 after 48 hrs by DAPI staining-based immunofluorescence analysis Antiplasmodial activity against liver stage of Plasmodium yoelii 17X NL sporozoites infected in human HepG2 cells expressing CD81 after 48 hrs by DAPI staining-based immunofluorescence analysis	[PMID: 25791675]
HepG2	CC₅₀	9.5 μM Compound: Atovaquone	Cytotoxicity against human HepG2 cells expressing CD81 assessed as cell viability after 72 hrs by CellTiter-glo assay Cytotoxicity against human HepG2 cells expressing CD81 assessed as cell viability after 72 hrs by CellTiter-glo assay	[PMID: 25791675]
Huh-7	IC₅₀	0.000376 μM Compound: ATV	Antiplasmodial activity against liver stage Plasmodium berghei infected in human HuH7 cells co-expressing GFP-Luccon treated for 1 hr prior to infection followed by 24 hrs after compound washout measured after 48 hrs post-infection by Alamar Blue assay Antiplasmodial activity against liver stage Plasmodium berghei infected in human HuH7 cells co-expressing GFP-Luccon treated for 1 hr prior to infection followed by 24 hrs after compound washout measured after 48 hrs post-infection by Alamar Blue assay	[PMID: 23701465]
Huh-7	IC₅₀	0.0018 μM Compound: ATQ	Antiplasmodial activity against liver-stage of Plasmodium berghei expressing firefly luciferase infected in human Huh-7 cells after 48 hrs by bioluminescence assay Antiplasmodial activity against liver-stage of Plasmodium berghei expressing firefly luciferase infected in human Huh-7 cells after 48 hrs by bioluminescence assay	[PMID: 26142491]
J774	EC₅₀	28 μM Compound: ATO	Cytotoxicity against mouse J774 cells after 72 hrs by CellTiter-96 aqueous one solution cell proliferation assay Cytotoxicity against mouse J774 cells after 72 hrs by CellTiter-96 aqueous one solution cell proliferation assay	[PMID: 29215279]
KB	IC₅₀	> 5 μg/mL Compound: atovaquone	Cytotoxicity against human KB cells assessed as [3H]hypoxanthine incorporation after 48 hrs Cytotoxicity against human KB cells assessed as [3H]hypoxanthine incorporation after 48 hrs	[PMID: 19199790]
MCF7	IC₅₀	1 μM Compound: Atovaquone	Inhibition of mammosphere formation in human MCF7 cells incubated for 5 days Inhibition of mammosphere formation in human MCF7 cells incubated for 5 days	[PMID: 33103432]
MRC5	IC₅₀	0.03 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate GRE-1995-MAE infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate GRE-1995-MAE infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.03 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii NED infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii NED infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.04 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate RMS-2005-HAG infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate RMS-2005-HAG infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.04 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate RMS-1994-LEF harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 204 sil Ala mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate RMS-1994-LEF harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 204 sil Ala mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.04 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate GUY-2003-MEL harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex2, 145 sil Val mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate GUY-2003-MEL harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex2, 145 sil Val mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.05 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii ME49 infected in human MRC-5 cells infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii ME49 infected in human MRC-5 cells infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.05 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate GRE-1998-TRA infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate GRE-1998-TRA infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.05 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii RH harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii RH harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.06 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate PSP-2005-MUP infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate PSP-2005-MUP infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.06 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate RMS-2001-MAU infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate RMS-2001-MAU infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.07 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii ENT harboring DHPS Ex2, E474D/Ex3, 156 sil Leu/Ex4, R560K/Ex5, 580 sil Gly/A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii ENT harboring DHPS Ex2, E474D/Ex3, 156 sil Leu/Ex4, R560K/Ex5, 580 sil Gly/A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.07 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate TRS-2004-REV infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate TRS-2004-REV infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.07 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate TOU-1998-TRI infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate TOU-1998-TRI infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.08 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate RMS-2003-DJO infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate RMS-2003-DJO infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.1 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii B1 harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii B1 harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.11 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate RMS-1995-ABE harboring DHPS Ex5, A587V mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate RMS-1995-ABE harboring DHPS Ex5, A587V mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
Raji	EC₅₀	> 21.5 μM Compound: 4	Cytotoxicity against human Raji cells after 72 hrs by luminescence analysis Cytotoxicity against human Raji cells after 72 hrs by luminescence analysis	[PMID: 22435599]

體外研究
(In Vitro)

Atovaquone 靶向線粒體電子傳遞鏈瘧原蟲(chóng)細(xì)胞色素 bc1 復(fù)合體的 Q_o 位點(diǎn)^[1]。
Atovaquone 有效抵抗蚊子從配子生產(chǎn)、受精、受精卵形成到成熟 ookinete 的發(fā)育，并證明 IC₅₀ 為 67 nM，進(jìn)一步證明了傳播阻斷潛力^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

Atovaquone (口服給藥；100 mg/kg；每天一次) 對(duì)小鼠存活率有抑制作用，口服給藥的小鼠在停用 Atovaquone 后22天內(nèi)死亡，而對(duì)照組小鼠在第14天死亡^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	ICSBP^?/??mice infected with 10 cysts of the ME49 strain of?T. gondii^[2]
Dosage:	100 mg/kg
Administration:	Oral administration
Result:	Improved mice survival rate to 22 days compared to vehicle.

Clinical Trial

分子量

366.84

Formula

C₂₂H₁₉ClO₃

CAS 號(hào)

95233-18-4

性狀

固體

顏色

Light yellow to yellow

中文名稱

阿托伐醌

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性數(shù)據(jù)

細(xì)胞實(shí)驗(yàn)：

DMSO 中的溶解度 : 8.33 mg/mL (22.71 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開(kāi)封的 DMSO)

配制儲(chǔ)備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	2.7260 mL	13.6299 mL	27.2598 mL
5 mM	0.5452 mL	2.7260 mL	5.4520 mL
10 mM	0.2726 mL	1.3630 mL	2.7260 mL

查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用。

摩爾計(jì)算器
稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶

方案一

請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 0.83 mg/mL (2.26 mM); 懸濁液; 超聲助溶

此方案可獲得 0.83 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。
以 1 mL 工作液為例，取 100 μL 8.3 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請(qǐng)依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 0.83 mg/mL (2.26 mM); 澄清溶液

此方案可獲得 ≥ 0.83 mg/mL（飽和度未知）的澄清溶液，此方案實(shí)驗(yàn)周期在半個(gè)月以上的動(dòng)物實(shí)驗(yàn)酌情使用。
以 1 mL 工作液為例，取 100 μL 8.3 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL玉米油中，混合均勻。

動(dòng)物溶解方案計(jì)算器

請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只

由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量

請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購(gòu)。，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。

計(jì)算結(jié)果

工作液所需濃度 : mg/mL

儲(chǔ)備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。

動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過(guò)半月以上，請(qǐng)謹(jǐn)慎選擇該方案。

請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 99.75%

選擇批次：

Data Sheet (653 KB) SDS (393 KB)

COA (286 KB) RP-HPLC (245 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Nilsen A, et al. Quinolone-3-diarylethers: a?new?class?of?antimalarial?drug.Sci Transl Med.?2013 Mar 20;5(177):177ra37. [Content Brief]

[2]. Sch?ler N, et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.Antimicrob Agents Chemother. 2001 Jun;45(6):1771-9. [Content Brief]

Atovaquone 相關(guān)分類(lèi)

完整儲(chǔ)備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.7260 mL	13.6299 mL	27.2598 mL	68.1496 mL
	5 mM	0.5452 mL	2.7260 mL	5.4520 mL	13.6299 mL
	10 mM	0.2726 mL	1.3630 mL	2.7260 mL	6.8150 mL
	15 mM	0.1817 mL	0.9087 mL	1.8173 mL	4.5433 mL
	20 mM	0.1363 mL	0.6815 mL	1.3630 mL	3.4075 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Atovaquone95233-18-4Atavaquone阿托伐醌ParasiteCytochrome P450AntibioticBacterialCYPsPlasmodiumneumocystispneumoniatoxoplasmosismalariababesiaInhibitorinhibitorinhibit

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機(jī)構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門(mén)：
* 公司或機(jī)構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。	站點(diǎn)地圖隱私聲明
滬ICP備15051369號(hào)-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營(yíng)業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Atovaquone (Synonyms: 阿托伐醌; Atavaquone)

Customer Review

Other Forms of Atovaquone:

MCE 顧客使用本產(chǎn)品發(fā)表的 4 篇科研文獻(xiàn)

Atovaquone 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 Parasite 亞型特異性產(chǎn)品:

查看 Cytochrome P450 亞型特異性產(chǎn)品:

查看 Antibiotic 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計(jì)算器

稀釋計(jì)算器

Atovaquone 相關(guān)分類(lèi)

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門(mén)區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Atovaquone (Synonyms: 阿托伐醌; Atavaquone)

Customer Review

Other Forms of Atovaquone:

Atovaquone 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 4 篇科研文獻(xiàn)

Atovaquone 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 Parasite 亞型特異性產(chǎn)品:

查看 Cytochrome P450 亞型特異性產(chǎn)品:

查看 Antibiotic 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻(xiàn)

Atovaquone 相關(guān)抗體:

摩爾計(jì)算器

稀釋計(jì)算器

Atovaquone 相關(guān)分類(lèi)

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門(mén)區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z